Inhibitor eradication with rituximab in haemophilia: where do we stand?

摘要: Rituximab is a humanized chimeric anti-CD20 monoclonal antibody initially developed for the treatment of some haematological malignancies. Thanks to its ability rapidly and specifically deplete B cells, it has also been used in variety autoimmune disorders, or not. In this context, during last decade several small case series have documented successful inhibitor eradication with rituximab, alone combination other immunosuppressive agents, patients acquired haemophilia A refractory standard therapy. addition, number investigators recently agent congenital alloantibodies first-line treatment. This article critically reviews current knowledge on use rituximab complicated by alloantibodies, providing algorithms management these conditions.